24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

NCT01517308 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial

Conditions

Interventions

Sponsor

Federico II University